A1RG34 Stock Overview
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
argenx SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €79.36 |
| 52 Week High | €104.20 |
| 52 Week Low | €64.33 |
| Beta | 0.36 |
| 1 Month Change | 0.61% |
| 3 Month Change | -1.98% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| A1RG34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 2.5% | 4.2% | 0.9% |
| 1Y | n/a | -2.6% | 15.2% |
Return vs Industry: Insufficient data to determine how A1RG34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how A1RG34 performed against the BR Market.
Price Volatility
| A1RG34 volatility | |
|---|---|
| A1RG34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: A1RG34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A1RG34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,148 | Tim Van Hauwermeiren | www.argenx.com |
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
argenx SE Fundamentals Summary
| A1RG34 fundamental statistics | |
|---|---|
| Market cap | R$116.22b |
| Earnings (TTM) | -R$1.50b |
| Revenue (TTM) | R$6.43b |
18.1x
P/S Ratio-77.7x
P/E RatioIs A1RG34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A1RG34 income statement (TTM) | |
|---|---|
| Revenue | US$1.27b |
| Cost of Revenue | US$977.33m |
| Gross Profit | US$291.27m |
| Other Expenses | US$586.32m |
| Earnings | -US$295.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -4.97 |
| Gross Margin | 22.96% |
| Net Profit Margin | -23.26% |
| Debt/Equity Ratio | 0% |
How did A1RG34 perform over the long term?
See historical performance and comparison